Cargando…
Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders
The effector functions of T lymphocytes are responsible for most autoimmune disorders and act by directly damaging tissues or by indirectly promoting inflammation and antibody responses. Co-stimulatory and co-inhibitory T cell receptor molecules are the primary pharmacological targets that enable in...
Autores principales: | Vanhove, Bernard, Poirier, Nicolas, Fakhouri, Fadi, Laurent, Laetitia, ’t Hart, Bert, Papotto, Pedro H., Rizzo, Luiz V., Zaitsu, Masaaki, Issa, Fadi, Wood, Kathryn, Soulillou, Jean-Paul, Blancho, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698823/ https://www.ncbi.nlm.nih.gov/pubmed/31548534 http://dx.doi.org/10.3390/antib6040019 |
Ejemplares similares
-
Antagonist properties of monoclonal antibodies to human CD28: role of valency and heavy-chain constant domain
por: Mary, Caroline, et al.
Publicado: (2012) -
Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015) -
Differential regulation of motility and immune synapses by CD28/ CTLA-4 costimulation in effector and regulatory T cells
por: Dilek, Nahzli, et al.
Publicado: (2012) -
Novel CD28 antagonist mPEG PV1-Fab’ mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production
por: Papotto, Pedro Henrique, et al.
Publicado: (2017) -
Evaluation of FR104, a Treg sparing antagonist anti-CD28 monovalent Fab’ antibody in kidney transplantation in non-human primates
por: Poirier, Nicolas, et al.
Publicado: (2012)